Jupiter Neurosciences (JUNS) stock will debut September 21 between $5 and $7 a share

Jupiter Neurosciences stock will IPO on September 21.
The biotech will trade under the ticker JUNS.
Management expects to raise appoximately $15 million.

Clay Webster FXStreet

Jupiter Neurosciences, a clinical stage biotech firm, will begin trading under the ticker JUNS on Wednesday, September 21. The IPO was first scheduled for September 9 and then September 14 before it was pushed back to Wednesday due to market volatility.

Founded in 2016 in Jupiter, Florida, Jupiter Neurosciences has just five employees, excluding all executives. The company is focused on its main resveratrol platform product called JOTROL, which is undergoing various phases of testing. JOTROL is thought to be effective for a number of different types of neural inflammation. These include Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, MELAS and early-stage ALS disease. Another use might be certain types of early onset Alzheimer's due to brain injury. The graphic below shows the various timelines for clinical testing for each disease or impairment.

Source: Jupiterneurosciences.com

Using bookrunner Spartan Capital, Jupiter Neurosciences plans to sell 2.5 million shares at a price per share between $5 and $7. This will help the company raise $15 million approximately to carry out the existing clinical trials. The firm has no major institutional backer or investor from the pharmaceutical industry.

"Based on our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operations through at least the next 24 months," reads the S-1 filing with the SEC.

Withstanding underwriter over-allotments, JUNS should IPO with a market cap somewhere between $50 and $60 million on September 21.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

EUR/USD meets initial support around 1.1800

EUR/USD remains on the back foot, although it has managed to reverse the initial strong pullback toward the 1.1800 region and regain some balance, hovering around the 1.1850 zone as the NA session draws to a close on Tuesday. Moving forward, market participants will now shift their attention to the release of the FOMC Minutes and US hard data on Wednesday.

GBP/USD bounces off lows, retargets 1.3550

After bottoming out just below the 1.3500 yardstick, GBP/USD now gathers some fresh bids and advances to the 1.3530-1.3540 band in the latter part of Tuesday’s session. Cable’s recovery comes as the Greenback surrenders part of its advance, although it keeps the bullish bias well in place for the day.

Gold remains offered below $5,000

Gold stays on the defensive on Tuesday, receding to the sub-$5,000 region per troy ounce on the back of the persistent move higher in the Greenback. The precious metal’s decline is also underpinned by the modest uptick in US Treasury yields across the spectrum.

Ethereum Price Forecast: BitMine extends ETH buying streak, says long-term outlook remains positive

Ethereum (ETH) treasury firm BitMine Immersion continued its weekly purchase of the top altcoin last week after acquiring 45,759 ETH.

UK jobs market weakens, bolstering rate cut hopes

In the UK, the latest jobs report made for difficult reading. Nonetheless, this represents yet another reminder for the Bank of England that they need to act swiftly given the collapse in inflation expected over the coming months.

Ripple slides to $1.45 as downside risks surge

Ripple edges lower at the time of writing on Tuesday, from the daily open of $1.48, as headwinds persist across the crypto market. A short-term support is emerging at $1.45, but a buildup of bearish positions could further weaken the derivatives market and prolong the correction.